Insulin Resistance Pipeline 2026: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Exscien Crp, Glycomantra, Hanmi Pharma, NorthSea Therapeutics, Amolyt Pharma